Advertisement
Advertisement
NBTX
Nanobiotix S.A. - ADR
30.54
USDSponsored
-0.05
-0.16%
Apr 10, 15:59 UTC -4
Closed
After-Market
30.27
-0.27
-0.87%
NBTX Earnings Reports
Positive Surprise Ratio
NBTX beat 4 of 16 last estimates.
25%
Next Report
Date of Next Report
May 19, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/--
Nanobiotix S.A. - ADR earnings per share and revenue
On Mar 31, 2026, NBTX reported earnings of -0.39 USD per share (EPS) for Q4 25, missing the estimate of 0.55 USD, resulting in a -170.16% surprise. Revenue reached 3.00 million, compared to an expected 59.82 million, with a -94.98% difference. The market reacted with a +10.37% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Nanobiotix S.A. - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Nanobiotix S.A. - ADR reported EPS of -$0.39, missing estimates by -170.16%, and revenue of $3.00M, -94.98% below expectations.
How did the market react to Nanobiotix S.A. - ADR's Q4 2025 earnings?
The stock price moved up 10.37%, changed from $30.87 before the earnings release to $34.07 the day after.
When is Nanobiotix S.A. - ADR expected to report next?
The next earning report is scheduled for May 19, 2026.
What are the forecasts for Nanobiotix S.A. - ADR's next earnings report?
Based on --
analysts, Nanobiotix S.A. - ADR is expected to report EPS of -- and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement